← Back to Screener
Guardant Health, Inc. Common Stock (GH)
Price$85.70
Favorite Metrics
Price vs S&P 500 (26W)25.93%
Price vs S&P 500 (4W)-8.58%
Market Capitalization$11.13B
All Metrics
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)21.93x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)29.76%
Cash Flow / Share (Quarterly)$-1.78
Price vs S&P 500 (YTD)-19.56%
Gross Margin (TTM)64.46%
Net Profit Margin (TTM)-42.39%
EPS (TTM)$-3.31
10-Day Avg Trading Volume2.30M
EPS Excl Extra (TTM)$-3.31
Revenue Growth (5Y)27.92%
EPS (Annual)$-3.32
ROI (Annual)-36.92%
Gross Margin (Annual)64.46%
Net Profit Margin (5Y Avg)-88.13%
Cash / Share (Quarterly)$9.20
Revenue Growth QoQ (YoY)39.37%
ROA (Last FY)-20.67%
Revenue Growth TTM (YoY)32.88%
EBITD / Share (TTM)$-3.25
ROE (5Y Avg)-296.29%
Operating Margin (TTM)-45.02%
Cash Flow / Share (Annual)$-1.78
P/B Ratio161.32x
P/B Ratio (Quarterly)35.72x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)12.48x
Net Interest Coverage (TTM)-150.95x
ROA (TTM)-27.91%
EV / EBITDA (TTM)195.14x
EPS Incl Extra (Annual)$-3.32
Current Ratio (Annual)4.84x
Quick Ratio (Quarterly)4.42x
3-Month Avg Trading Volume2.01M
52-Week Price Return87.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.50
P/S Ratio (Annual)11.33x
Asset Turnover (Annual)0.49x
52-Week High$120.74
Operating Margin (5Y Avg)-87.43%
EPS Excl Extra (Annual)$-3.32
CapEx CAGR (5Y)-2.23%
Tangible BV CAGR (5Y)-31.91%
26-Week Price Return29.91%
Quick Ratio (Annual)4.42x
13-Week Price Return-21.11%
Total Debt / Equity (Annual)7.18x
Current Ratio (Quarterly)4.84x
Enterprise Value$12,256.921
Revenue / Share Growth (5Y)21.65%
Asset Turnover (TTM)0.66x
Book Value / Share Growth (5Y)-25.36%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)4.45x
Pretax Margin (Annual)-42.52%
Cash / Share (Annual)$9.20
3-Month Return Std Dev52.72%
Gross Margin (5Y Avg)63.53%
Net Income / Employee (TTM)$-0
ROE (Last FY)-302.14%
Net Interest Coverage (Annual)-0.76x
EPS Basic Excl Extra (Annual)$-3.32
Receivables Turnover (TTM)7.92x
Total Debt / Equity (Quarterly)16.78x
EPS Incl Extra (TTM)$-3.31
Receivables Turnover (Annual)7.92x
ROI (TTM)-34.74%
P/S Ratio (TTM)11.33x
Pretax Margin (5Y Avg)-86.91%
Revenue / Share (Annual)$7.83
Tangible BV / Share (Annual)$1.23
Price vs S&P 500 (52W)58.08%
Year-to-Date Return-16.92%
5-Day Price Return-2.65%
EPS Normalized (Annual)$-3.32
ROA (5Y Avg)-27.19%
Net Profit Margin (Annual)-42.39%
Month-to-Date Return-8.13%
Cash Flow / Share (TTM)$-3.61
EBITD / Share (Annual)$-3.25
Operating Margin (Annual)-45.02%
LT Debt / Equity (Annual)7.18x
ROI (5Y Avg)-27.18%
LT Debt / Equity (Quarterly)16.77x
EPS Basic Excl Extra (TTM)$-3.31
P/TBV (Quarterly)40.60x
P/B Ratio (Annual)20.69x
Inventory Turnover (TTM)4.45x
Pretax Margin (TTM)-42.52%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)-21.80%
Beta1.58x
Revenue / Share (TTM)$7.63
ROE (TTM)-246.60%
52-Week Low$36.36
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.30
4.28
4.29
4.29
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $85.70 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $196.11 |
LHLabcorp Holdings Inc. | 25.08x | 7.25% | 9.92% | 10.28% | $266.36 |
DGXQuest Diagnostics Inc. | 21.24x | 11.78% | 14.10% | 13.88% | $191.46 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.09 |
VCYTVeracyte, Inc. | 40.04x | 16.01% | 11.17% | 5.33% | $33.03 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $49.47 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $22.42 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.09 |
CSTLCastle Biosciences, Inc. Common Stock | 47.31x | 3.66% | -12.44% | -5.27% | $24.56 |
About
Guardant Health is a liquid biopsy leader providing blood-based cancer tests for clinical detection and monitoring. The company's core franchises include Guardant360 for tumor genomic profiling, Reveal for molecular residual disease monitoring, and Shield for colorectal cancer screening. Guardant also offers regulatory consulting and clinical trial support services for the oncology research market.